1State Key Laboratory of Membrane Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, 100101, China.
2State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China.
3National Laboratory of Biomacromolecules, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China.
4University of Chinese Academy of Sciences, Beijing 100049, China.
5Beijing Advanced Innovation Center for Genomics, Biomedical Pioneering Innovation Center, School of Life Sciences, Peking University, Beijing 100871, China.
6Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing 100871, China.
7Advanced Innovation Center for Human Brain Protection, National Clinical Research Center for Geriatric Disorders, Xuanwu Hospital Capital Medical University, Beijing 100053, China.
F. Hoffmann-La Roche Ltd
Roche launches cobas PIK3CA Mutation Test for patients with advanced or metastatic breast cancer in countries accepting the CE mark
Roche launches cobas PIK3CA Mutation Test for patients with advanced or metastatic breast cancer in countries accepting the CE mark
This genetic test identifies mutations in the PIK3CA gene that can cause cells to grow uncontrollably, which may lead to cancer
PIK3CA is the most commonly mutated gene in advanced or metastatic breast cancer, with nearly 40 percent of patients harbouring a mutation in this gene
1
The cobas PIK3CA Mutation Test is a PCR-based test that detects PIK3CA mutations in patients with metastatic breast cancer to help identify those most likely to benefit from approved therapy
Share:
This genetic test identifies mutations in the PIK3CA gene that can cause cells to grow uncontrollably, which may lead to cancer
PIK3CA is the most commonly mutated gene in advanced or metastatic breast cancer, with nearly 40 percent of patients harbouring a mutation in this gene
1
The cobas PIK3CA Mutation Test is a PCR-based test that detects PIK3CA mutations in patients with metastatic breast cancer to help identify those most likely to benefit from approved therapy
2
Basel, 15 December 2020 - Roche ((SIX: RO, ROG, OTCQX:RHHBY) today announced the launch of the cobas® PIK3CA Mutation Test for patients with advanced or metastatic breast cancer. Previously only available as research use only (RUO), this in vitro diagnostic (IVD) test is now available in countries accepting the CE mark.
Roche launches cobas PIK3CA Mutation Test for patients with advanced or metastatic breast cancer in countries accepting the CE mark – IT Business Net itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.
(2)
This genetic test identifies mutations in the PIK3CA gene that can cause cells to grow uncontrollably, which may lead to cancer
PIK3CA is the most commonly mutated gene in advanced or metastatic breast cancer, with nearly 40 percent of patients harbouring a mutation in this gene
1
The cobas PIK3CA Mutation Test is a PCR-based test that detects PIK3CA mutations in patients with metastatic breast cancer to help identify those most likely to benefit from approved therapy
2
Basel, 15 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the cobas PIK3CA Mutation Test for patients with advanced or metastatic breast cancer. Previously only available as research use only (RUO), this in vitro diagnostic (IVD) test is now available in countries accepting the CE mark.